Cytokinetics, Inc. (CYTK)
61.95
-1.97
(-3.08%)
USD |
NASDAQ |
Oct 16, 16:00
61.97
+0.02
(+0.03%)
After-Hours: 20:00
Cytokinetics Free Cash Flow : -580.72M for June 30, 2026
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| June 30, 2026 | -580.72M |
| March 31, 2026 | -548.92M |
| December 31, 2025 | -534.82M |
| September 30, 2025 | -453.38M |
| June 30, 2025 | -438.72M |
| March 31, 2025 | -407.57M |
| December 31, 2024 | -399.80M |
| September 30, 2024 | -407.05M |
| June 30, 2024 | -401.27M |
| March 31, 2024 | -422.57M |
| December 31, 2023 | -415.75M |
| September 30, 2023 | -443.03M |
| June 30, 2023 | -434.57M |
| March 31, 2023 | -403.38M |
| December 31, 2022 | -310.85M |
| September 30, 2022 | -271.95M |
| June 30, 2022 | -238.46M |
| March 31, 2022 | -185.41M |
| December 31, 2021 | -191.39M |
| September 30, 2021 | -83.31M |
| June 30, 2021 | -17.06M |
| March 31, 2021 | -7.078M |
| December 31, 2020 | -2.109M |
| September 30, 2020 | -68.06M |
| June 30, 2020 | -101.11M |
| Date | Value |
|---|---|
| March 31, 2020 | -97.54M |
| December 31, 2019 | -93.53M |
| September 30, 2019 | -85.70M |
| June 30, 2019 | -97.02M |
| March 31, 2019 | -99.20M |
| December 31, 2018 | -102.10M |
| September 30, 2018 | -114.42M |
| June 30, 2018 | -107.76M |
| March 31, 2018 | -112.37M |
| December 31, 2017 | -104.64M |
| September 30, 2017 | -2.81M |
| June 30, 2017 | 10.70M |
| March 31, 2017 | 30.98M |
| December 31, 2016 | 35.39M |
| September 30, 2016 | -51.74M |
| June 30, 2016 | -49.71M |
| March 31, 2016 | -47.84M |
| December 31, 2015 | 4.321M |
| September 30, 2015 | 6.09M |
| June 30, 2015 | 6.875M |
| March 31, 2015 | 6.437M |
| December 31, 2014 | -45.95M |
| September 30, 2014 | -50.25M |
| June 30, 2014 | -30.40M |
| March 31, 2014 | -14.02M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| Bristol Myers Squibb Co. | 11.44B |
| Alnylam Pharmaceuticals, Inc. | 793.94M |
| BioMarin Pharmaceutical, Inc. | 725.08M |
| Exelixis, Inc. | 1.172B |
| Ionis Pharmaceuticals, Inc. | -567.50M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -159.84M |
| Cash from Investing (Quarterly) | -507.00M |
| Cash from Financing (Quarterly) | 792.86M |
| Free Cash Flow Per Share (Quarterly) | -1.243 |
| Free Cash Flow to Equity (Quarterly) | -146.01M |
| Free Cash Flow to Firm (Quarterly) | -129.34M |
| Free Cash Flow Yield | -7.53% |